{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382825895236935682.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Jerry S. Wolinsky"}],"foaf:familyName":[{"@value":"Wolinsky"}],"foaf:givenName":[{"@value":"Jerry S."}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362825895236935680","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1056/nejmoa1606468"},{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1606468"}],"notation":[{"@value":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa1606468_Ljr5K295uO4cO0NcjRg1c06TFLZ"}]}